# K-Basket, Avelumab, Biomarker-driven, Advanced Solid Tumor

> **NCT03491345** · PHASE2 · UNKNOWN · sponsor: **Yonsei University** · enrollment: 60 (estimated)

## Conditions studied

- PD-L1 Positive Mutation Tumor
- EBV Positive Mutation Tumor
- MSI-H Mutation Tumor
- POLE/POLD1 Mutation Tumor

## Interventions

- **DRUG:** Avelumab

## Key facts

- **NCT ID:** NCT03491345
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-08-01
- **Primary completion:** 2022-08
- **Final completion:** 2022-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2022-08-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03491345

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03491345, "K-Basket, Avelumab, Biomarker-driven, Advanced Solid Tumor". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03491345. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*